Core Viewpoint - Peijia Medical-B (09996) has seen a significant stock increase of over 11%, with an expected annual revenue growth of approximately 40% for the upcoming fiscal year [1] Financial Performance - The company anticipates revenue for the fiscal year 2024 to be between 610 million to 630 million, representing a year-on-year growth of approximately 38.3% to 42.8% [1] - The growth is primarily driven by the rapid expansion of the company's entire neuro-interventional product line and an increase in market share in the transcatheter aortic valve replacement (TAVR) sector in China [1] Market Position and Strategy - According to research from CICC, Peijia Medical's diverse product matrix is expected to help the company adapt to future competitive landscape changes, allowing it to maintain its leading position in the valve market [1] - Huatai Securities noted that the company is seizing industry opportunities to solidify its TAVR market share, with new TAVR/TMV products expected to be approved for commercialization by 2025 [1] - The company is also expected to improve operational efficiency, with a potential for profitability by 2026, maintaining a "buy" rating [1]
港股异动 | 沛嘉医疗-B(09996)再涨超11% 下周二将发年度业绩 公司预计全年收入同比增长约四成